Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image

( 1 )

Overview

While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D ...

See more details below
Other sellers (Paperback)
  • All (9) from $23.48   
  • New (8) from $23.48   
  • Used (1) from $29.94   

Overview

While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals.

Read More Show Less

Editorial Reviews

From the Publisher
"Oz should invite LaMattina back on his show. Since LaMattina treats all concerns respectfully, Oz needn’t worry about feeling devalued or distrusted." (Barron's, 5 May 2014)

“This is an honest book by an insider who believes in the basic good that the industry does.” (The Quarterly Review of Biology, 1 September 2013)

“Summing Up: Recommended. General audiences.” (Choice, 1 September 2013)

“For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show.” (ChemMedChem, 19 July 2013)

“That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading.” (Chemistry & Industry, 1 June 2013)

“John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the "Dr. Oz" show.” (In The Pipeline, 1 December 2012)

Read More Show Less

Product Details

  • ISBN-13: 9781118487471
  • Publisher: Wiley
  • Publication date: 1/9/2013
  • Edition number: 1
  • Pages: 136
  • Product dimensions: 6.00 (w) x 9.10 (h) x 0.50 (d)

Meet the Author

JOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley).

Read More Show Less

Table of Contents

ACKNOWLEDGMENTS ix

INTRODUCTION 1

CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON’T WANT YOU TO KNOW 4

Drug Companies Underestimate Dangerous Side Effects 5

Drug Companies Control Much of the Information Your Doctor Gets 10

You’re Often Prescribed Drugs That You Don’t Need 14

Drugs Target the Symptoms, Not the Cause 19

Conclusion 22

References 23

CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY? 25

Impact of Mergers on R&D Productivity 26

Heightened FDA Requirements for NDAs 34

Higher Hurdles Set by Payers 41

Conclusion 46

References 48

CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49

Cancer 51

Diseases of the Brain 54

Cardiovascular Disease (CVD) 60

Diabetes 63

Bacterial Infections 65

Conclusion 68

References 69

CHAPTER 4 IMPROVING R&D OUTPUT 71

The Views of Others 72

Pharma’s Blockbuster Mentality Needs to Change 72

Can “Predictive Innovation” Lead to Greater Success Rates? 76

Would Royalties Make Scientists More Productive? 78

Will Drug Repositioning Help Fill the R&D Pipeline? 80

Consultants Don’t Always Have the Facts 82

Personal Views 84

Discovery Must Focus on Productivity 85

Does Size Help or Hinder R&D Productivity? 87

To Outsource or Not to Outsource? That’s the Pharma R&D Question 89

Big Pharma Early Research Collaborations 92

Conclusion 93

References 95

CHAPTER 5 RESTORING PHARMA’S IMAGE 96

Illegal Detailing of Drugs 97

Pharmaceutical Companies Should Drop TV Ads 98

The Need for Greater Transparency 100

How Committed Is Big Pharma to Rare Diseases? 102

Pharmaceutical Companies and Philanthropy 104

Pharma Needs to Have Its Scientists Tell Their Stories 105

Conclusion 106

References 107

CHAPTER 6 FINAL THOUGHTS 109

References 114

INDEX 115

Read More Show Less

Customer Reviews

Average Rating 5
( 1 )
Rating Distribution

5 Star

(1)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously
Sort by: Showing 1 Customer Reviews
  • Anonymous

    Posted April 16, 2013

    TRAINING ROOM

    Was this review helpful? Yes  No   Report this review
Sort by: Showing 1 Customer Reviews

If you find inappropriate content, please report it to Barnes & Noble
Why is this product inappropriate?
Comments (optional)